Mehr lesen
According to the National Alliance on Mental Illness 1 in 5 adults (46.6 million) experiences mental illness in a given year. With that number steadily increasing every year it is vital that we invest into new drug discoveries as treatment options. At present the number of drugs available to treat individual with psychiatric disorders varies widely, and it is crucially important to identify new therapeutic targets in order to develop new, effective drugs.
Therapeutic Discovery in Psychiatry aims to provide researchers with a complete guide to new technologies and techniques that can effectively manage risk and deliver of new drugs for psychiatric disorders. This book not only addresses issues of reproducibility, but addresses other topics including, drug profiling in vitro, examining drug targets, brain circuits and behavior, medicinal chemistry, drug formulation and pharmacokinetics, and much more.
Therapeutic Discovery in Psychiatry is a prime resource for researchers who are trying to understand the field of psychopharmacology.
Inhaltsverzeichnis
1. Pharmacology basics
2. Neuroscience basics
3. Immunology basics
4. History of Psychopharmacology
5. Getting past serendipity
6. Drug Profiling in vitro
7. Drug Profiling in vivo
8. Brain imaging
9. Neurobiology Imaging and genetics of Psychiatric Disorders
10. Developmental disorders
11. Choosing drug targets:
12. Ethics of animal use
13. Biomarkers of drug action
14. Monitoring regional neuronal activation, fMRI, oxygen amperometry, optogenetics
15. Medicinal Chemistry
16. Design of experimental medicine studies for Clinical Proof of Concept
17. Drug formulation and Pharmacokinetics, including nanoscience The Blood Brain Barrier
18. Safety Pharmacology
19. Clinical trial design
20. Drug targets that failed clinically: what went wrong?
21. Genomics in drug discovery and target validation
22. Clinical translation
23. Business Development and licensing
24. Patent law
25. Entrepreneurial development and venture capitol
26. Pharmacovigilence and regulatory agencies, FDA and EMA
27. Examples of success and innovation
Über den Autor / die Autorin
Dr. Mark David Tricklebank, BSc MSc PhD DSc FBphS, earned his PhD from the University of Manchester, and after completing postdoctoral training at the Institute of Neurology, he joined the pharmaceutical company Merrell Dow in Strasbourg, where he was instrumental in the identification of the functional relevance of the newly identified 5-HT1A recognition site. He then moved to Merck at Terlings Park, where he worked with Susan Iversen to identify the behavioral effects of the NMDA receptor antagonist MK-801 and showed them to be identical to those of phencyclidine and ketamine. After then serving as head of the Mental Health Unit at Sandoz Pharma in Basel, he was appointed director of In Vivo Pharmacology at the Lilly Research Centre, Windlesham, where he conceived and founded the Lilly Centre for Cognitive Neuroscience, one of the first industrial-academic partnerships in the United Kingdom. After a varied career of several decades in the pharmaceutical industry, he now serves as a Wellcome Trust Fellow in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, and has published more than 160 papers.
